Prospective Observational study of Sitagliptin in Subjects with type 2 Diabetes and Chronic Renal Failure
Latest Information Update: 05 Mar 2018
Price :
$35 *
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms POSEIDON
- 01 Mar 2018 Status changed from active, no longer recruiting to completed.
- 28 Feb 2015 New trial record